Literature DB >> 17161164

Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Richard T Penson1, Lari B Wenzel, Ignace Vergote, David Cella.   

Abstract

Quality of life (QOL) is a fundamental consideration for patients with life threatening diseases. Major evolving paradigms are discussed: improved QOL with laparoscopic surgery, the impact on QOL of intraperitoneal chemotherapy for optimally cytoreduced ovarian cancer, combination therapy, sexuality, and survivorship. The goals of treatment for many patients with gynecologic tumors remain largely palliative, and patient reported QOL is the primary outcome determining the utility of treatment. Particularly in this area, QOL endpoints are increasingly important in clinical trials. The QOL issues facing gynecologic cancer patients, the use of validated QOL instruments, recent advances in the evaluation of interventions, and changes in concepts related to QOL are reviewed.

Entities:  

Mesh:

Year:  2006        PMID: 17161164     DOI: 10.1016/S0020-7292(06)60040-4

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  14 in total

1.  Barriers to urogynecological care in a population of gynecological oncology patients.

Authors:  Paula Jaye Doyle; Sajeena G Thomas; Gunhilde M Buchsbaum
Journal:  Int Urogynecol J       Date:  2016-11-17       Impact factor: 2.894

2.  HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.

Authors:  Rafael Molina; Jose M Escudero; Jose M Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa
Journal:  Tumour Biol       Date:  2011-08-24

3.  Prevalence of pelvic floor disorders in women with suspected gynecological malignancy: a survey-based study.

Authors:  C Emi Bretschneider; Kemi M Doll; Jeannette T Bensen; Paola A Gehrig; Jennifer M Wu; Elizabeth J Geller
Journal:  Int Urogynecol J       Date:  2016-02-12       Impact factor: 2.894

4.  Perioperative adverse events in women undergoing concurrent urogynecologic and gynecologic oncology surgeries for suspected malignancy.

Authors:  Emily R W Davidson; Katherine Woodburn; Mariam AlHilli; Cecile A Ferrando
Journal:  Int Urogynecol J       Date:  2018-10-02       Impact factor: 2.894

5.  Validity and reliability of the European Organization for Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ): experience from Kuwait using a sample of women with breast cancer.

Authors:  Shafika A Alawadhi; Jude U Ohaeri
Journal:  Ann Saudi Med       Date:  2010 Sep-Oct       Impact factor: 1.526

Review 6.  Quality-of-life issues in the management of epithelial ovarian cancer.

Authors:  Thomas Lowe; Betty Ferrell; Lucille Leong
Journal:  Curr Treat Options Oncol       Date:  2007-12

Review 7.  Ovarian cancer survivors' quality of life: a systematic review.

Authors:  D Ahmed-Lecheheb; F Joly
Journal:  J Cancer Surviv       Date:  2016-02-17       Impact factor: 4.442

Review 8.  Distress and quality of life characteristics associated with seeking surgical treatment for stress urinary incontinence.

Authors:  Karen M Gil; Amber M Somerville; Sara Cichowski; Jennifer L Savitski
Journal:  Health Qual Life Outcomes       Date:  2009-02-05       Impact factor: 3.186

9.  Factors associated with quality of life of outpatients with breast cancer and gynecologic cancers and their family caregivers: a controlled study.

Authors:  Abdel W Awadalla; Jude U Ohaeri; Abdullah Gholoum; Ahmed O A Khalid; Hussein M A Hamad; Anila Jacob
Journal:  BMC Cancer       Date:  2007-06-19       Impact factor: 4.430

10.  Evaluation of the psychometric properties of the Functional Assessment of Cancer Therapy-Cervix questionnaire in Brazil.

Authors:  Cristiane Menezes Sirna Fregnani; José Humberto Tavares Guerreiro Fregnani; Maria do Rosário Dias de Oliveira Latorre; Ana Maria de Almeida
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.